Stefan W. Hell
Nobel Laureate Professor
Director, Max Planck Institute for Biophysical Chemistry
Dept. of NanoBiophotonics
University of Göttingen
Germany
Nobel Laureate Dr. Stefan W. Hell pioneered the physical concepts for breaking the diffraction barrier in a microscope using conventional lenses. His innovations include development of STED microscopy and related concepts and discovery of the on-off switching of (fluorescence) signal as key mechanism for overcoming the diffraction resolution limit.
At present Stefan W. Hell is a director at the Max Planck Institute for Biophysical Chemistry in Göttingen, where he leads the Department of NanoBiophotonics. He is an honorary professor of experimental physics at the University of Göttingen and adjunct professor of physics at the University of Heidelberg. Since 2003, he also led the Optical Nanoscopy division at the German Cancer Research Center (DKFZ) in Heidelberg.
Stefan W. Hell received his diploma (1987) and doctorate (1990) in physics from the University of Heidelberg. From 1991 to 1993 he worked at the European Molecular Biology Laboratory, also in Heidelberg, and followed with stays as a senior researcher at the University of Turku, Finland, between 1993 and 1996, and as a visiting scientist at the University of Oxford, England, in 1994. In 1997 he was appointed to the MPI for Biophysical Chemistry in Göttingen as a group leader and was promoted in 2002 to director.
Stefan W. Hell is credited with having conceived, validated and applied the first viable concept for overcoming Abbe’s diffraction-limited resolution barrier in a light-focusing fluorescence microscope. For this accomplishment he has received several awards: most recently he shared the 2014 Kavli Prize in Nanoscience and the Nobel Prize in Chemistry.
Gordon G. Wallace
Professor
Australian Research Council Laureate Fellow
Executive Research Director of the Australian Research Council Centre of Excellence for Electromaterials Science
Director of the Intelligent Polymer Research Institute, University of Wollongong, Australia
Director of the Australian National Fabrication Facility, Materials Node
Professor Gordon G. Wallace is involved in the design and discovery of new materials for use in Energy and Health. In the Health area this involves using new materials to develop biocommunications from the molecular to skeletal domains in order to improve human performance via medical bionics. In the Energy area this involves use of new materials to transform and to store energy, including novel wearable and implantable energy systems for the use in medical bionics. He is committed to the translation of fundamental discoveries into practical applications.
Professor Wallace completed his undergraduate (1979) and Ph.D. (1983) degrees at Deakin University, and was awarded a D.Sc. also from Deakin University in 2000. He was appointed as a Professor at the University of Wollongong in 1990. He was awarded an ARC Professorial Fellowship in 2002, an ARC Federation Fellowship in 2006 and ARC Laureate Fellowship in 2011. He is also a Fellow of the Australian Academy of Science, Australian Academy of Technological Sciences and Engineering (ATSE), Institute of Physics, and Royal Australian Chemical Institute (RACI).
Recently Professor Wallace was appointed to the Australian Prime Ministers Knowledge Nation 100.
Professor Wallace has supervised almost 100 PhD students to completion and has mentored more than 50 research fellows. He has published more than 800 refereed publications that have attracted in excess of 25,000 citations; a monograph (3rd Edition published in 2009) on Conductive Electroactive Polymers: Intelligent Polymer Systems and co-authored a monograph on Organic Bionics (published 2012). He has recently co-authored an eBook on 3D BioPrinting and led the presentation of a MOOC on 3D Bioprinting on the FutureLearn platform.
Manuel Bardiès
PhD, Research Director
Cancer Research Center of Toulouse
UMR1037 INSERM – Université Toulouse 3, France
Manuel Bardiès obtained his doctorate on radiopharmaceutical dosimetry from Paul Sabatier University (Toulouse III) in November 15, 1991. He has been developing his research in radiopharmaceutical dosimetry within INSERM (National Institute of Health and Medical Research), since 1992, in Nantes then in Toulouse (2011). In both locations he has been the research director of various projects. His current project is entitled “Multi-resolution dosimetry for radiotherapy optimization”.
Dr. Bardiès has been appointed to several international positions. He was one of the founders of the EANM Dosimetry Committee (member from 2001 to 2013, chair 2009-2011). He is the current chair of EFOMP Science Committee.
The team led by Manuel Bardiès in Toulouse is primarily involved in radiopharmaceutical dosimetry, at various scales (cell, tissue, organs). This requires the ability to assess radiopharmaceutical pharmacokinetics in vivo, through quantitative SPECT or PET small-animal imaging. An important part of research activity is related to Monte-Carlo modelling of radiation transport through biological structures of interest, in order to give account of energy deposition within tumour targets – or critical non-tumour tissues/organs. The objective is to improve molecular radiotherapy by allowing patient-specific treatments, as an important application of personalized medicine.
Risto Ilmoniemi
Academy Professor
Department of Neuroscience and Biomedical Engineering
Aalto University, Helsinki, Finland
Academy Professor Risto Ilmoniemi is a physicist and neuroscientist at Aalto University.
He received the Ph.D. degree in physics from the Helsinki University of Technology (HUT) in 1985. He developed biomagnetic theory and technology in the Low Temperature Laboratory of HUT (1978–85 and 1987–93) and at New York University (1985–87). Many of his inventions and methods of magnetoencephalography (MEG) were commercially exploited by the HUT startup company Neuromag Ltd. (now part of Elekta Ltd.). From 1993 until 2003 he was the head of the BioMag Laboratory at Helsinki University Hospital. Dr. Ilmoniemi is founder (2000), former Chairman and CEO (until 2005) of Nexstim Ltd. (NXTMH:FH), a company that introduced navigated transcranial magnetic stimulation (TMS) and the combined use of TMS and EEG.
Since 2006, he has been professor of Applied Physics at Aalto University; he is member of the Finnish Academy of Science and Letters and member of the Finnish Academy of Technical Sciences. Currently, he is developing, among other things, hybrid MEG and magnetic resonance imaging (MEG–MRI) technology, new methods for TMS as well as solutions to the biomagnetic inverse problem. He is also pursuing work in fundamental and clinical neuroscience; he has taught the course Structure and Operation of the Human Brain since 1989. Ilmoniemi’s 250 publications have been cited over 20,000 times. He is inventor or co-inventor in more than 10 patents.
Serge Mordon
Professor, PhD
Director of INSERM U 1189 (Image Assisted Laser Therapies Assisted for Oncology) at the French National Institute of Health and Medical Research (INSERM)
Director of the Photomedicine Center at Lille University Hospital
Professor Serge R. Mordon, PhD, works in Lille, France, for the French National Institute of Health and Medical Research (INSERM). He is the director of INSERM U 1189 (Image Assisted Laser Therapies Assisted for Oncology), and the director of the Photomedicine Center (Lille University Hospital).
Since 1981, he has been involved in the medical applications of lasers, particularly in dermatology and plastic surgery. More recently, he has focused his research on Focal Laser Ablation and Photodynamic Therapy. He is an internationally recognized expert in laser-tissues interaction and laser applications in medicine. He has authored over 400 articles and book chapters. Professor Mordon is also the author of sixteen issued patents.
Since 2012, he holds a Master Degree in Strategy and Organization Management (University of Paris X). He is the President of The French Medical Laser Society and Board Member of several professional societies. He is an associate editor of the editorial board for the journal, Lasers in Surgery and Medicine. In 2015, he has been nominated Finland Distinguished Professor.
Jukka-Pekka Onnela
Assistant Professor of Biostatistics
Harvard T.H. Chan School of Public Health
Harvard University
United States
Jukka-Pekka “JP” Onnela is Assistant Professor in the Department of Biostatistics at Harvard University.
He obtained his doctorate in network science in Aalto University (formerly Helsinki University of Technology) in 2006 where his doctoral dissertation received dissertation of the year award. He subsequently spent two years at the University of Oxford as a Junior Research Fellow, a year at the Harvard Kennedy School as a Fulbright Visiting Scholar, and two years as a Postdoctoral Fellow at Harvard Medical School. He joined his current department in 2011, where he runs a research group that focuses on statistical network science (study of network representations of social and biological systems) and digital phenotyping (moment-by-moment quantification of the individual-level human phenotype in situ using smartphones). He was awarded NIH (U.S. National Institutes of Health) Director’s New Innovator Award in 2013 for his work in digital phenotyping.
Molly M. Stevens
Professor, FREng, FRPharmS, FIMMM, FRSC, FRSB
Professor of Biomedical Materials and Regenerative Medicine & Research Director for Biomedical Material Sciences
Imperial College London
United Kingdom
Molly M. Stevens is currently Professor of Biomedical Materials and Regenerative Medicine & Research Director for Biomedical Material Sciences in the Department of Materials, Department of Bioengineering and the Institute of Biomedical Engineering at Imperial College London. She received her PhD from The University of Nottingham in 2000. She then conducted her postdoctoral research within the Department of Chemical Engineering at MIT in the laboratory of Prof Robert Langer.
Molly Stevens joined Imperial College in 2004 and was promoted as Professor in 2008. Research in the Stevens Programme focusses on designing and developing innovative bio-inspired materials for applications in regenerative medicine, tissue engineering and biosensing.
Professor Stevens’ research has been recognised by over 20 major awards, such as the 2016 Clemson Award for Basic Research from the Society for Biomaterials, the EU40 Prize for best material scientist under the age of 40, a listing in The Times as one of the top 10 scientists under 40 and the European Life Sciences 2014 Research Group of the Year Award, amongst many others. She was recently elected to the Fellowship of the Royal Academy for Engineering and delivered the Clifford Paterson Lecture for the Royal Society in 2012.
Professor Stevens has published over 200 publications in regenerative medicine, tissue engineering, materials science and biosensing and has an h-index > 50. She serves as Reviewing Editor of Science and Associate Editor of ACS Nano. More information on the Stevens Group can be found at http://www.stevensgroup.org.
Anthony P.F. Turner
Professor, PhD, DSc, FRSC, IVA
Head of the Biosensors and Bioelectronics Centre
Linköping University
Sweden
Professor Anthony (Tony) Turner’s name is synonymous with the field of Biosensors. In 2010, he joined Linköping University to create a new Centre for Biosensors and Bioelectronics. His previous thirty-five year academic career in the UK culminated in the positions of Principal of Cranfield University at Silsoe and Distinguished Professor of Biotechnology; he is now an Emeritus Professor at Cranfield. In addition to his academic and management roles, he had overall responsibility there for leveraging Cranfield University’s IP via spin outs and licensing.
In 2016, Prof Turner was awarded the Ukraine’s highest academic honour, the Vernadsky Gold Medal from the National Academy of Sciences. He was elected to the Royal Swedish Academy of Engineering Sciences in 2013 and was made a Fellow of the UK Royal Society of Chemistry in 1996. He was awarded a Higher Doctorate (DSc) for his exceptional contribution to biosensors by the University of Kent in 2001 and an Honorary DSc by the University of Bedfordshire in 2008, where he served as a Governor for six years. He was admitted as a Foreign Associate of the USA National Academy of Engineering in 2006, for his work on glucose sensors, environmental monitors and synthetic recognition molecules and is a Visiting Professor at various universities in the UK, Italy, Korea, Japan and China.
Anthony Turner has over 750 publications and patents (>350 refereed journal papers and reviews) in the field of biosensors and biomimetic sensors and is probably best known for his role in the development of commercial glucose sensors for home-use by people with diabetes. He has an h-index of 73. He published the first textbook on Biosensors in 1987, is Editor-In-Chief of the principal journal in his field, Biosensors & Bioelectronics (Elsevier) and chairs the World Congress on Biosensors, which he founded in 1990.
anthony.turner@liu.se
www.ifm.liu.se/biosensors
http://en.wikipedia.org/wiki/Tony_Turner_(scientist)
http://scholar.google.co.uk/citations?user=SfilpLAAAAAJ&hl=en
E.M.J. (Sabeth) Verpoorte
Chair of Analytical Chemistry and Pharmaceutical Analysis
Groningen Research Institute of Pharmacy
University of Groningen
The Netherlands
E.M.J. (Sabeth) Verpoorte has more than 26 years of research experience in the lab-on-a-chip field, starting in 1990 as a postdoctoral researcher and later as staff research scientist in the pioneering lab-on-a-chip group headed by Professor A. Manz at Ciba Ltd., Basel, Switzerland. In July 1996 she assumed the position of team leader in the group of Professor Nico F. de Rooij at the Institute of Microtechnology (IMT), University of Neuchâtel, Switzerland, where her research interests concentrated on the lab-on-a-chip area for bioanalytical and environmental applications. She successfully led a research team of 5 PhD students and 3 postdocs while at IMT.
Sabeth Verpoorte has been head of the Pharmaceutical Analysis Group in the Groningen Research Institute of Pharmacy, University of Groningen, since 2003. Research in the Pharmaceutical Analysis group is devoted to better understanding micro- and nanofluidic systems and how they can be applied to chemical and cell biological problems. A major driving force for Verpoorte’s research continues to be the acquisition of projects involving scientists from the life sciences, chemical, and physics disciplines, focusing on relevant questions related to drug development and unraveling the underlying mechanisms of disease.
Her present research has taken on a strong cell biological / pharmacological focus, and includes innovative joint projects with colleagues in pharmacokinetics and medical biology on integrated cell and tissue culture and analysis. Ongoing projects involve chip-based human endothelial cell culture and analysis, and the development of organ-on-a-chip systems to study drug metabolism (liver chip, gut chip) and organ interactions (intestine-liver chip). Recent acquisition of national and EU funding have helped expand Verpoorte’s efforts in both these areas. Efforts have also concentrated on continuous-flow particle separation strategies, as well as miniaturized analytical instrumentation (paper spray ionization, multidimensional chromatography). She is or has been involved in several international scientific organizations and journal editorial boards.